Excessive Daytime Sleepiness (EDS) - Epidemiology Forecast - 2036

Excessive Daytime Sleepiness (EDS) Insights and Trends

• Excessive Daytime Sleepiness (EDS) is a clinical condition characterized by an inability to maintain wakefulness and alertness during the daytime, often resulting from disruptions in normal sleep-wake regulation. It is commonly associated with underlying disorders such as narcolepsy, obstructive sleep apnea, and circadian rhythm disturbances, rather than being a standalone disease entity.
• The underlying pathology of EDS involves dysregulation of key neurobiological pathways that control arousal and sleep, including the orexin (hypocretin) system, dopaminergic signaling, and other central nervous system mechanisms. Impairment in these pathways leads to excessive sleep propensity, reduced alertness, and impaired cognitive function during waking hours.
• Clinically, EDS presents with persistent daytime drowsiness, difficulty maintaining attention, unintended sleep episodes, and reduced productivity. In severe cases, it can significantly impair daily functioning, increase the risk of accidents, and negatively impact quality of life. The severity of symptoms varies depending on the underlying cause and comorbid conditions.
• Diagnosis is based on comprehensive clinical evaluation, sleep history assessment, and objective testing such as polysomnography and the multiple sleep latency test (MSLT). Advances in sleep medicine and increased awareness are supporting earlier and more accurate identification of EDS and its underlying etiologies.

DelveInsight's 'Excessive Daytime Sleepiness (EDS) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the EDS, historical and forecasted epidemiology of the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

Excessive Daytime Sleepiness (EDS) Understanding

Excessive Daytime Sleepiness (EDS) Overview and Diagnosis

EDS is a clinical condition characterized by an inability to maintain wakefulness and alertness during the day, often resulting in unintended lapses into sleep. It is commonly associated with underlying sleep disorders such as narcolepsy, obstructive sleep apnea, and circadian rhythm disturbances, as well as neurological or psychiatric conditions. Patients typically present with persistent drowsiness, reduced concentration, and impaired daily functioning. Diagnosis involves a comprehensive clinical evaluation, sleep history assessment, and objective testing such as polysomnography and the multiple sleep latency test (MSLT). Advances in sleep diagnostics are enabling more accurate identification of underlying causes, supporting targeted management strategies.

Excessive Daytime Sleepiness (EDS) Epidemiology

Key Findings from Excessive Daytime Sleepiness (EDS) Epidemiological Analysis and Forecast

• The total number of diagnosed prevalent cases of Excessive Daytime Sleepiness (EDS) in the 7MM was around 7,800,000 in 2025.
• The United States has the highest diagnosed prevalence of Excessive Daytime Sleepiness (EDS), around 4,200,000 in 2025.
• Among EU4 and the UK, the UK accounts for the highest number of prevalent cases of Excessive Daytime Sleepiness (EDS), whereas Spain accounts for the least number of prevalent cases.
• As per the DelveInsight analysis, it was observed that Japan accounted for approximately 16% diagnosed prevalent population of EDS among 7MM, in the year 2025.

Scope of the Report:

• The report covers a segment of a descriptive overview of EDS, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Excessive Daytime Sleepiness (EDS) Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) bottom-up forecasting
• 11-year forecast
• Patient Burden trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of EDS? What will be the growth opportunities across the 7MM concerning the patient population with EDS?
• What is the historical and forecasted EDS patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.